New Mexico Makes History with Senate Bill 219 — The Medical Psilocybin Act

New Mexico Makes History with Senate Bill 219 — The Medical Psilocybin Act

In a landmark move during the 2025 legislative session, New Mexico enacted Senate Bill 219 — the Medical Psilocybin Act, a pioneering piece of legislation that establishes a state-regulated medical psilocybin program to help New Mexicans suffering from some of the most challenging mental and emotional health conditions. (New Mexico Legislature)

Legislative Leadership and Approval

A broad coalition of lawmakers brought SB 219 forward, reflecting bipartisan support and years of groundwork by advocates, health professionals, and community volunteers. State senators and representatives sponsoring the bill included Senator Jeff Steinborn (D-Las Cruces), Senator Martin Hickey (D-Albuquerque), Senator Craig W. Brandt (R-Rio Rancho), Senator Shannon Pinto (D), Senator Elizabeth “Liz” Stefanics (D), Representative Elizabeth “Liz” Thomson (D-Albuquerque), Representative Andrea Romero (D-Santa Fe), and Representative Stefani Lord (R), among others. (New Mexico Legislature)

After passing the Senate and House with decisive majorities, SB 219 was signed into law by Governor Michelle Lujan Grisham on April 7, 2025 — a significant achievement in state healthcare innovation. (Governor's Office NM)

Qualifying Conditions for Care

Under the new law, the Medical Psilocybin Act allows psilocybin to be used in an approved clinical setting to treat patients diagnosed with specific qualifying conditions, including:

• Major treatment-resistant depression

• Post-traumatic stress disorder (PTSD)

• Substance use disorders

• End-of-life care and death-related psychological distress

  
  

These initial qualifying conditions reflect both clinical research and the priorities of advocates who have long championed expanded care options for individuals facing profound suffering. (New Mexico Legislature)

The Department of Health (DOH) also has authority to consider additional conditions in the future, opening a path for the program to evolve based on emerging science and patient needs. (New Mexico Legislature)

A Triumph of Volunteer Advocacy and Community Action

The passage of SB 219 didn’t happen in a vacuum — it came after years of tireless advocacy by volunteers, community organizers, clinicians, tribal representatives, and lived-experience leaders across New Mexico. Grassroots groups held town halls, submitted testimony, supported research briefs, and educated lawmakers and the public about the potential of psilocybin-assisted therapy. Their commitment helped build the awareness and political will necessary to move such a transformative bill through committee hearings and onto the governor’s desk.

This volunteer energy from people around the state exemplified New Mexico’s spirit of collaborative problem-solving and caring for neighbors in crisis.

Building the Program — What’s Still to Come

While the law authorizes the creation of the medical psilocybin program, many key details remain under development as the state transitions from statute to operational reality:

• How patients will qualify — Criteria for clinical eligibility, documentation requirements, and referral pathways are still being shaped.

• Who can provide care — Training standards, licensing pathways, and professional scopes for clinicians and facilitators are in progress under DOH rulemaking.

• Treatment protocols — Protocols for safe administration, preparation, and integration sessions, dosage standards, and approved settings will be developed with input from the Medical Psilocybin Advisory Board and stakeholders. (New Mexico Department of Health)

The advisory board — mandated by the Act to include experts, tribal members, behavioral health advocates, veterans, and healthcare authority representatives — will be essential in drafting guidelines, recommending additional qualifying conditions, and shaping best practices. (New Mexico Legislature)

The law also establishes equity and research funds to support access for low-income patients and to fuel ongoing scientific study connected to psilocybin therapy. (New Mexico Legislature)

A Program Poised to Evolve

Full implementation of the program is targeted by December 31, 2027, but leaders across the state anticipate adapting and expanding the system over time — well beyond the first year launch — to improve accessibility, refine clinical standards, and ensure community needs are met. This includes ongoing discussions around insurance reimbursement, Medicaid coverage, and equitable access to care for uninsured and rural New Mexicans. In December of 2025 key partners projected roll out one year ahead of schedule by December of 2026.

Why This Matters in New Mexico

New Mexico faces some of the highest rates of suicide, substance use disorder, and unmet behavioral health needs in the nation. By creating a regulated pathway for innovative treatment, SB 219 represents more than policy change — it is a response to real suffering faced by families across the state. The Act reflects New Mexico’s values: compassion, cultural respect, community engagement, and a willingness to explore bold solutions rooted in evidence and humanity.

As implementation unfolds, New Mexico will continue charting new territory, setting examples for how states can build responsible, patient-centered psychedelic medicine programs while honoring local voices and protecting vulnerable populations.